Appealing Xolair Food Allergy Coverage Denials

New FDA Indication

In February 2024, Xolair (omalizumab) became the first FDA-approved treatment to reduce allergic reactions to food, including accidental exposure, in patients aged 1 year and older.

Why Insurers Deny Food Allergy Xolair

1. Outdated criteria — plan criteria only list asthma or chronic urticaria
2. New indication lag — insurer hasn't updated formulary for 2024 approval
3. Cost concerns — Xolair is expensive (~$2,500/month)
4. Experimental classification — incorrectly classifying as experimental

Appeal Arguments

FDA Approval Is Definitive

• FDA approved February 2024 for IgE-mediated food allergy
• Based on OUtMATCH trial (multi-food allergy phase 3)
• Ages 1 year and older

Clinical Need

• Patient has documented IgE-mediated food allergies
• History of anaphylaxis or severe allergic reactions
• Food avoidance alone is insufficient — accidental exposure is common
• Xolair provides a meaningful safety net against accidental ingestion

Documentation Needed

• Allergist letter with specific food allergy diagnoses
• IgE levels and skin prick test results
• History of allergic reactions and anaphylaxis events
• Citation of FDA approval and OUtMATCH trial data
• Explanation that Xolair supplements (not replaces) food avoidance

Important Note

Xolair does NOT eliminate food allergies — patients must still avoid allergens. It raises the threshold for reactions, providing protection against accidental exposure.